Portal hypertension remains a major determinant of clinical outcomes in patients with hepatocellular carcinoma (HCC). In patients with unresectable disease treated with atezolizumab-bevacizumab, hepatic decompensations (variceal hemorrhage, ascites, or hepatic encephalopathy) may limit treatment and worsen survival.
Yet current tools used to assess portal hypertensive risk remain either invasive or insufficiently adapted to this population. In this issue of the Journal of Hepatology, Rabasco Meneghetti et al.
Journal of Hepatology published a clinical update in Research Highlights on 01 Apr 2026.
The item focuses on Artificial intelligence uncovers latent signals of portal hypertension in routine CT imaging.
Review the original article for the full source wording and details.